Takeda Pharmaceutical Company Limited

Calpis Co., Ltd.

Shuji Kitamura

Yasutomi Asano

Takashi Ueyama

Koji Watanabe

Tsuneo Yasuma

Takuto Kojima

Shinichi Imamura

Zenichi Ikeda

Tzu-Tshin Wong

Yasufumi Miyamoto

Yasuhiro Hirata

Fumio Itoh

Yuta Tanaka

Osamu Kurasawa

Hideki Hirose

Takafumi Yukawa

Kazuko Yonemori

Naoki Iwamura

Minoru Ikoma

Sachie Morimoto

Ryosuke Arai

Bunnai Saito

Osamu Sano

Masaki Seto

Masato Yoshida

Hiroyuki Kimura

Haruhi Ando

Masaki Kawamura

Hiroshi Banno

Kazuaki Takami

Taiji Asami

Nobuyuki Takakura

Yoshihide Tomata

Hironobu Maezaki

Atsuko Ochida

Ayumu Sato

Naoki Nishizawa

Nobuyuki Negoro

Kenjiro Sato

Yoshihiro Banno

Shinobu Sasaki

Nozomu Sakai

Yoshito Terao

Tomohiro Kawamoto

Steve Swann

Kei Masuda

Takashi Motoyaji

Hideki Igata

Mitsuru Sasaki

Takahisa Matsuda

Arai Ryosuke

The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.

Heterocyclic compounds having a calcium-sensing receptor antagonistic activity

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Condensed-cyclic compound

Heterocyclic compound

The present invention provides a medicament for preventing or treating heart failure. More specifically, the present invention provides a medicament for preventing or treating heart failure, comprising a compound selected from the group consisting of (5R)&#x2014;N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)&#x2014;N-[1-ethyl-1-(4-methoxyphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)&#x2014;N-[1-ethyl-1-(4-ethylphenyl)propyl]-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and salts thereof.

Medicament for treating heart failure

The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

There are disclosed methods for producing fermented milk and whey that enable effective production in high yield of fermented milk and whey having high content of an ACEI peptide that is highly safe and applicable to pharmaceuticals, functional foods, health foods, and the like. The methods are: a method including the steps of mixing lactic acid bacteria and a starting material containing milk by stirring to prepare a mixed material, and fermenting the mixed material under stirring so that curd pieces and whey containing an angiotensin converting enzyme inhibitory peptide are generated, whereby fermented milk containing the curd pieces and the whey containing the angiotensin converting enzyme inhibitory peptide is produced; and a method including the steps of subjecting the resulting fermented milk to centrifugation and/or filter pressing to separate and recover whey.

Method for producing fermented milk containing angiotensin converting enzyme inhibitory peptide and method for producing whey

The present invention aims at provision of a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. The compound represented by the formula: wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonistic activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents as agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.

Alkoxyphenylpropanoic acid derivatives

The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. They unexpectedly show superior GPR40 receptor agonist activity, and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor related diseases in mammals. 

3-(4-benzyloxyphenyl) propanoic acid derivatives

A JNK inhibitor containing a compound having an isoquinolinone skeleton or a salt thereof, such as a compound represented by the formula wherein ring A and ring B are each an optionally substituted benzene ring, X is &#x2014;O&#x2014;, &#x2014;N&#x2550;, &#x2014;NR&#x2014; or &#x2014;CHR&#x2014;, Ris an acyl group, an optionally esterified or thioesterified carboxyl group, an optionally substituted carbamoyl group or an optionally substituted amino group and the like, a broken line shows a single bond or a double bond, and Ris a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group and the like, and the like.

JNK inhibitor

Novel carbamate derivatives which are useful as drugs because of inhibiting activated blood coagulation factor X and thus exerting an anticoagulant effect. Compounds represented by the formula: wherein Rrepresents a group represented by the formula: (wherein Yrepresents CH&#x2550;CH, etc.), which may be substituted, etc.; the ring A represents an oxo-substituted nitrogen-containing heterocyclic ring which may be further substituted; Rrepresents a hydrogen atom, optionally substituted Calkyl, etc.; Rrepresents optionally substituted Calkyl, etc.; and Z represents an optionally substituted nitrogen containing heterocyclic group, etc., or salts thereof.

Carbamate derivatives, process for producing the same and use thereof

Process for producing granules containing angiotensin-converting enzyme inhibiting peptides

In a method of purifying whey separated from lactic acid fermentation liquid by electrodialysis wherein said whey contains angiotensin-converting enzyme inhibiting peptides, the improvement which comprises using an anion exchange membrane having a permeability of diffusion coefficient in the range of 3.0 to 9.0&times;10,cm/sec. An anion exchange membrane having a permeability of diffusion coefficient in the range of 5.0 to 7.0&times;10,cm/sec. is more efficiently used. The product is particularly suited to produce granules and tablets.

Method of purifying whey of lactic acid fermentation by electrodialysis

Growing community of inventors

Kanagawa, Japan

Shuji Kitamura